You are here

BCRF Grantee Since


Donor Recognition

The Radar Tires [Omni United] Award

Area(s) of Focus

Jack Cuzick, PhD

Professor of Epidemiology
Queen Mary, University of London
Australia and New Zealand Breast Cancer Trials Group
Cancer Research UK
London, United Kingdom

Current Research

Well-designed randomized clinical trials may provide information about prevention strategies and effective treatments for women at risk of, or diagnosed with, breast cancer. A major limitation of clinical trials, however, is that results apply to the trial group as a whole, but not necessarily to each individual woman, because individual responses are influenced by the patient’s and the tumor’s unique DNA, or genetic profile. The goal of the BCRF research led by Drs. Forbes and Cuzick is to more precisely identify risks for individual women, who have a very high or very low chance of getting breast cancer based on testing of molecular markers. To do this, they are building a High Risk Breast Bio-Bank (HRBB) to discover new protein and gene biomarkers from blood, tumor tissue and mammograms that can predict outcomes for the prevention and treatment of breast cancer. Their goal is to collect reliable clinical outcome data and tissue with long-term follow-up of individual women in prevention and treatment trials to reduce risks for women. In the coming year, the research team will continue follow-up of women on the International Breast Intervention Study (IBIS)-I, IBIS-II and LATER trials to collect tissues and long-term clinical outcomes for biomarker discovery. IBIS-I is a primary prevention trial for pre- and postmenopausal women at increased risk of BC, testing tamoxifen for chemoprevention. IBIS-II is a similar trial for postmenopausal women, testing anastrozole. LATER is a long-term treatment trial testing letrozole for a further five years for women disease free five years after diagnosis. Drs. Forbes and Cuzick will continue tissue collection for the HRBB and analyses of clinical outcome data and biomarkers to improve prediction of risks for the trial population. As new breast cancer trials including (a) the pilot study IBIS III, a study investigating prevention of late recurrence in ER+ breast cancer survivors following 5 years of adjuvant treatment; and (b) ELIMINATE, a randomized phase II neoadjuvant trial with or without concurrent aromatase inhibitor endocrine therapy, are activated, tissue collected from these trials will also be added to the HRBB, expanding this excellent resource for future translational research.


Jack Cuzick is a Director of the Wolfson Institute of Preventive Medicine in London. He is also head of the Centre for Cancer Prevention and John Snow Professor of Epidemiology at Queen Mary, University of London. He holds a PhD in Mathematics and has previously worked at Oxford University and Columbia University, New York. His current interests are in cancer epidemiology and clinical trials, with special interest in prevention and screening. He is currently Chairman of the International Breast Cancer Intervention Study (IBIS) Steering Group and the ATAC trial. He has worked extensively in breast cancer and was the first to report the effect of tamoxifen on contralateral tumors as an indicator of its potential chemopreventive role and also has demonstrated that a change in mammographic breast density on endocrine treatment is a biomarker for its effectiveness. He is involved in studies on the use of HPV assays for cervical screening, the use of flexible sigmoidoscopy for colorectal cancer screening and markers for the behavior of early prostate cancer. He is a Fellow of the Academy of Medical Sciences, the Royal Statistical Society, the Institute of Mathematical Statistics and an Honorary Fellow of the Royal College of Physicians. In 2007, he was chosen by Thompson Scientific as one of the twelve hottest researchers in all of science. He was awarded the AACR Cancer Prevention Prize in 2012. He is the author of 520 peer-reviewed papers and has published in all the major medical journals.